Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: oral

Currently viewing:

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
Started on April 2, 1979.
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Old study, but well documented and scientifically acceptable.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1979
Report date:
1979

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Principles of method if other than guideline:
The acute oral LD50 of the test item in rats of both sexes was assessed administering three doses at 5000, 6500, 8000 and 10000 mg/kg bw. Animals were observed over a period of 14 days.
GLP compliance:
no
Remarks:
Pre GLP
Test type:
standard acute method

Test material

Constituent 1
Chemical structure
Reference substance name:
Tetrasodium 4,4'-bis[[4-[(2-hydroxyethyl)amino]-6-(m-sulphonatoanilino)-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
EC Number:
240-400-4
EC Name:
Tetrasodium 4,4'-bis[[4-[(2-hydroxyethyl)amino]-6-(m-sulphonatoanilino)-1,3,5-triazin-2-yl]amino]stilbene-2,2'-disulphonate
Cas Number:
16324-27-9
Molecular formula:
C36H32N12Na4O14S4
IUPAC Name:
Tetrasodium 2,2'-[(E)-1,2-ethenediyl]bis[5-({4-[(2-hydroxyethyl)amino]-6-[(3-sulfonatophenyl)amino]-1,3,5-triazin-2-yl}amino)benzenesulfonate]

Test animals

Species:
rat
Strain:
other: Tif RAIf (SPF) strain
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: animals were raised on the premises were used for these experiments.
- Age at study initiation: 7 to 8 weeks old.
- Weight at study initiation: males in the range of 168-199 g; females in the range of 159-177 g.
- Housing: during the treatment and observation period the animals were housed in groups of 5 in Macrolon cages (type 3).
- Diet: ad libitum rat food - NAFAG, Gossau SG.
- Water: ad libitum.
- Acclimation period: for a minimum of 4 days.

ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 2 °C
- Humidity: 55 ± 10 %
- Photoperiod: 10 hours light cycle day.

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
CMC (carboxymethyl cellulose)
Remarks:
2 %
Details on oral exposure:
- Volume: 20 ml/kg
Doses:
5000, 6500, 8000 and 10000 mg/kg bw
No. of animals per sex per dose:
5 x sex x group.
Details on study design:
- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes; animals were at random to a necropsy at the end of the observation period.
- Examinations performed: bodyweights were recorded immediately prior to dosing (control weights) and at 7 and 14 days.
Statistics:
LD50 including 95 % confidence limits were calculated by the logit model.

Results and discussion

Effect levels
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 10 000 mg/kg bw
Based on:
test mat.
Mortality:
No dead occurred at all the doses tested.
Clinical signs:
other: The rats in all dosage groups showed sedation, dyspnoea, exophthalmus, curved position and ruffled fur. The animals recovered within 6 to 7 days.
Gross pathology:
No substance related gross organ changes were seen.

Any other information on results incl. tables

Rate of deaths

Dose mg/kg Sex No. of animals No. of animals dead Death rate %
5000 M 5 0 0
6500 M 5 0 0
8000 M 5 0 0
10000 M 5 0 0
5000 F 5 0 0
6500 F 5 0 0
8000 F 5 0 0
10000 F 5 0 0

Signs and symptoms

5000 mg/kg bw

Signs and symptoms Hours Days
1 2 3 5 24 2 3 4 5 6 7 8 9 10 11 12 13 14
Sedation + + + + +
Dyspnoea + + + + + + + + +
Dacryorrhoea
Chromodacryorrhoea
Rinorrhoea
Epistaxis
Exophthalmos ++ ++ + + + +
Salivation
Ruffled fur + + + + + +
Pallor
Cyanosis
Diarrhoea
Body position (ventral)
Body position (lateral)
Body position (curved) + + + + + + + + +
Ataxia
Trismus
Tremor
Tonic clonic muscle spasms
Convulsions

 + = slight, ++ = moderate, +++ = severe

6500 mg/kg bw

Signs and symptoms Hours Days
1 2 3 5 24 2 3 4 5 6 7 8 9 10 11 12 13 14
Sedation + + + + +
Dyspnoea + + + + + + + + +  +
Dacryorrhoea
Chromodacryorrhoea
Rinorrhoea
Epistaxis
Exophthalmos ++ ++ ++ ++ + +  +  +
Salivation
Ruffled fur + + + + + +  +
Pallor
Cyanosis
Diarrhoea
Body position (ventral)
Body position (lateral)
Body position (curved) + + + + + + + + +
Ataxia
Trismus
Tremor
Tonic clonic muscle spasms
Convulsions

 + = slight, ++ = moderate, +++ = severe

8000 mg/kg bw

Signs and symptoms Hours Days
1 2 3 5 24 2 3 4 5 6 7 8 9 10 11 12 13 14
Sedation + + + + +
Dyspnoea + + + + + + + + +  +
Dacryorrhoea
Chromodacryorrhoea
Rinorrhoea
Epistaxis
Exophthalmos ++ ++ ++ ++ + +  +  
Salivation
Ruffled fur + + + + + +  +  +
Pallor
Cyanosis
Diarrhoea
Body position (ventral)
Body position (lateral)
Body position (curved) + + + + + + + + +
Ataxia
Trismus
Tremor
Tonic clonic muscle spasms
Convulsions

 + = slight, ++ = moderate, +++ = severe

10000 mg/kg bw

Signs and symptoms Hours Days
1 2 3 5 24 2 3 4 5 6 7 8 9 10 11 12 13 14
Sedation + + + + +  +  +
Dyspnoea + + + + + + + + +  +
Dacryorrhoea
Chromodacryorrhoea
Rinorrhoea
Epistaxis
Exophthalmos ++ ++ ++ ++ + +  +  
Salivation
Ruffled fur + + + + + +  +  +
Pallor
Cyanosis
Diarrhoea
Body position (ventral)
Body position (lateral)
Body position (curved) + + + + + + + +
Ataxia
Trismus
Tremor
Tonic clonic muscle spasms
Convulsions

 + = slight, ++ = moderate, +++ = severe

Bodyweight changes

Dose 5000 6500 8000 10000
Day 1 M Mean BW/SD (g) 168/4.8 184/12.9 199/12.1 190/7.4
Day 1 F 177/3.7 159/7.1 177/3.4 172/5.9
Day 7 M 268/5.9 240/10.7 244/22.4 247/11.4
Day 7 F 209/9.5 185/5.5 203/6.0 198/7.9
Day 14 M 272/15.3 282/17.4 292/11.5 280/17.4
Day 14 F 266/9.2 198/6.4 221/10.4 210/11.3

Applicant's summary and conclusion

Interpretation of results:
not classified
Remarks:
Migrated information According to the CLP Regulation. Criteria used for interpretation of results: EU
Conclusions:
LD50 > 10000 mg/kg bw
Executive summary:

Method

The acute oral LD50 of the test item in rats of both sexes was assessed administering three doses at 5000, 6500, 8000 and 10000 mg/kg bw. Animals were observed over a period of 14 days.

Results

No dead occurred at all the doses tested. The rats in all dosage groups showed sedation, dyspnoea, exophthalmus, curved position, diarrhoea and ruffled fur; the animals recovered within 7 to 10 days.

LD50 > 10000 mg/kg bw